Immunoglobulins (IgG, IgA, IgM)
Immunoglobulin A (IgA) is an antibody that plays a crucial role in the immune function of mucous membranes. It comprises about 15% of serum gamma globulins. As a major secretory immunoglobulin in our body this class of immunoglobulins serves as the primary antibody in saliva, tears, milk, gastrointestinal and respiratory mucosa. IgA plays an important role in protection of mucosal lining from infection. There are two classes: IgA1 and IgA2. IgA usually circulates in serum as a single unit; however, it is usually in less concentration in secretory fluids. Increased monoclonal IgA is seen in lymphoproliferative disorders such as multiple myeloma, lymphoma and leukemia. Monoclonal IgA is also seen in “Mediterranean” lymphoma involving bowel and monoclonal gammopathy of undetermined significance (MGUS). Increased levels of IgA are also commonly seen in chronic liver disease such as primary biliary cirrhosis, in chronic infections, chronic inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, other connective tissue diseases and sarcoidosis. Idiopathic IgA nephropathy (Berger Disease) is the most common primary glomerulonephritis caused by elevated levels of IgA deposited in glomerular mesangial membranes. Decreased levels of IgA (IgA deficiency) results in respiratory bacterial infections. IgA deficiency is closely associated with diarrheal parasitic disease giardiasis. IgA deficiency is seen in hereditary telangiectasia, type III dysgammaglobulinemia, systematic lupus erythematosus (SLE), Still’s disease, Waldenstrom macroglobulinemia, gastric carcinoma and in celiac disease (especially in children).
Immunoglobulin G (IgG) is a major circulating immunoglobulin and it represents almost 80% of the total immunoglobulins in our body. It exists in four subclasses: IgG1, IgG2, IgG3 and IgG4, with IgG1 being predominating at more than 65% of total IgG in our body. Significant decrease in IgG level, whether on a congenital or acquired basis, is associated with an increased susceptibility to infections. In contrast, IgG levels will be increased in immunocompetent patients responding to a wide variety of infections or inflammatory agents. However, the major cause for polyclonal increase is IgG is the acquired immunodeficiency syndrome. Oligoclonal IgG can occur in multiple sclerosis, and in some cases of chronic immune hepatitis. Decrease in IgG <300mg/dL with normal or increased IgM and IgD levels will lead to susceptibility to pyogenic and opportunistic infections. This condition is often inherited as an X-linked or autosomal recessive disease that occurs due to failure of activated T lymphocytes to activate B cells to proliferate and produce IgG antibody. IgG is the only immunoglobulin group that crosses the placenta, and maternal IgG will be protective as it provides passive immunity to neonates.
Immunoglobulin M (IgM) comprises 5% to 10% of total immunoglobulins. IgM is the initial antibody type secreted during the primary humoral response to antigen. IgM serves as the first antibody barrier. IgM is the only antibody that binds an antigen it has not previously been exposed to. When exposed, the typical antibody response will lead to an increase in antigen-specific IgM, resulting in isotype switching, and then a subsequent increase in antigen-specific immunoglobulins of other classes (seroconversion). IgM antibody response is considered an acute response, and if elevated or produced in infection, it is considered an acute infection. In contrast, IgG is considered a secondary response to infection, also known as chronic infection. IgM has five subunits (pentameric structure) joined with a joining J-chain, which gives 10 sites for antibody binding. Due to its pentameric structure, the IgM antibody cannot cross the placenta. Elevation of immunoglobulin M may occur in monoclonal gammopathies such as macroglobulinemia, primary systemic amyloidosis, monoclonal gammopathy of undetermined significance, and related disorders. Decreased levels are found in patients with primary or secondary immune deficiencies.
- Evaluate anaphylaxis associated with transfusion of blood and blood products
- As an aid in diagnosis of Celiac diseases
- As an aid in diagnosis of IgA nephropathy
- As an aid in diagnosis of psoriatic arthritis
- As an aid in diagnosis of multiple myeloma
- As an aid in diagnosis and management of monoclonal gammopathies
- As an aid in diagnosis of monoclonal gammopathy of undetermined significance
- As an aid in management of patients with lymphoma and leukemia
- As an aid in diagnosis and management of immune deficiencies
- As an aid in diagnosis of autoimmune disorders
- Monitor and manage chronic or recurrent infections
- As an aid in diagnosis and management of macroglobulinemia
- As an aid in diagnosis and management of Waldenstrom syndrome
- Differential diagnosis plasma cell myeloma (IgM myeloma)
- Differential diagnosis of essential macroglobulinemia
Increased in:
- Monoclonal gammopathy of undetermined significance (MGUS)
- Multiple myeloma
- Systemic lupus erythematosus (SLE)
- Liver Cirrhosis
- Chronic hepatitis
- Primary systemic amyloidosis
- Inflammatory bowel diseases
- Sarcoidosis
- Wiskott-Aldrich syndrome
- Lymphoma
- Chronic lymphocytic leukemia
- Ankylosing spondylitis
- Viral infection
- Bacterial infection (gram-negative bacteria)
- Parasitic infections
- Chronic inflammatory conditions
- Rheumatoid arthritis
- Primary biliary cirrhosis
- Nephrotic syndrome
- Hyper IgM syndrome
- Waldenstrom macroglobulinemia
- µ-heavy chain disease
- Schnitzler syndrome
- Monoclonal gammopathies of undetermined significance
- Chronic infection
- Autoimmune pancreatitis
- Autoimmune hepatitis
- Solitary plasmocytoma
- Gamma heavy chain disease
- Monoclonal gammopathy of undetermined significance
- Lymphoma
- Chronic lymphocytic leukemia
Decreased in:
- Liver cirrhosis
- Nephrotic syndrome
- Type III dysgammaglobulinemia
- Enteropathy
- Ataxia-telangiectasia
- Primary or secondary immune disorders
- Waldenstrom macroglobulinemia
- Acquired immunodeficiency
- Gastric carcinoma
- Immunodeficiency state
- Monoclonal gammopathies
- Splenectomy
- Enteric protein loss
- Thermal burns
- Immunosuppressant drug use
- X-linked agammaglobulinemia
- Protein losing enteropathy
- Treatment with immunosuppressants
- Myotonic dystrophy
- Other immunocompromised disorders
| Immunoglobulin A – Age Group | Reference Range |
| 0–1 years | 0-83 mg/dl |
| 1–3 years | 20-100 mg/dl |
| 4–6 years | 27-195 mg/dl |
| 7–9 years | 34-305 mg/dl |
| 10–11 years | 53-204 mg/dl |
| 12–13 years | 58-358 mg/dl |
| 14–15 years | 47-305 mg/dl |
| 16–18 years | 78-348 mg/dl |
| ≥19 years | 85-400 mg/dl |
| Immunoglobulin G – Age Group | Reference Range |
| Adults | 565-1660 mg/dL |
| 1 month | 250-900 mg/dL |
| 2-5 months | 200-700 mg/dL |
| 6-9 months | 200-900 mg/dL |
| 10-12 moths | 290-1050 mg/dL |
| 1-3 years | 350-1200 mg/dL |
| 4-6 years | 450-1500 mg/dL |
| 7-9 years | 650-1600 mg/dL |
| 10-15 years | 700-1650 mg/dL |
| Immunoglobulin M – Age Group | Reference Range |
| Adults | 50-350 mg/dL |
| 1 month | 20-80 mg/dL |
| 2-5 months | 25-100 mg/dL |
| 6-9 months | 35-125 mg/dL |
| 10-12 months | 40-150 mg/dL |
| 1-8 years | 45-200 mg/dL |
| 9-12 years | 50-250 mg/dL |
| 12-16 years | 50-300 mg/dL |
Serum (SST), cerebrospinal fluid collected in a sterile container or tube.
Stability
- Ambient: 48 hours
- Refrigerated: 7 days
- Frozen: 28 days
- Nat Rev Immunol. 2003 Jan;3(1):63-72. [PMID: 12511876]
- J Biol Chem. 2009 Feb 20;284(8):5077-87. [PMID: 19109255]
- Semin Immunol. 2007 Apr;19(2):127-35. [PMID: 17161619]
- Curr Opin Immunol. 2008 Apr;20(2):170-7. [PMID: 18456485]
- Trends Immunol. 2008 Nov;29(11):523-31. [PMID: 18838301]
- Liver Int. 2017 Apr 22. doi: 10.1111/liv.13458. [PMID: 28432836]
- Dig Dis Sci. 2017 Apr 1. doi: 10.1007/s10620-017-4541. [PMID: 28365915]
- Clin Biochem. 2017 May 4. pii: S0009-9120(16)30742-1. [PMID: 28479151]
- Hematol Oncol Clin North Am. 2014 Oct;28(5):775-90. [PMID: 25212882]
- Ann Intern Med. 1971 Nov;75(5):673-82. [PMID: 5122154]
- Am J Med. 1984 Mar 30;76(3A):7-18. [PMID: 6369977]
- Am J Med. 1984 Mar 30;76(3A):1-6. [PMID: 6369973]
- Crit Rev Clin Lab Sci. 1989;27(1):27-58. [PMID: 2647414]
- N Engl J Med. 1996 Nov 21;335(21):1570-80. [PMID: 8900092]
- Liver Int. 2017 Apr 22. doi: 10.1111/liv.13458. [PMID: 28432836]
- Dig Dis Sci. 2017 Apr 1. doi: 10.1007/s10620-017-4541. [PMID: 28365915]
- Clin Biochem. 2017 May 4. pii: S0009-9120(16)30742-1. [PMID: 28479151]
- Mary Williamson, L. Michael Snyder. Wallach’s Interpretation of Diagnostic Testing, 9th ed. Lippincott Williams and Wilkins (Wolters Kluwer); 2011
- Alan H.B Wu. Clinical Guide to Laboratory Tests, 4th ed. WB Saunders Company; 2006. Fischbach FT, Dunning MB III, eds. Manual of Laboratory and Diagnostic Tests, 8th ed. Philadelphia: Lippincott Williams; 2009.